chrisvoncsefalvay/vaers-outcomes huggingface dataset:
No adverse effects were reported; Patients were administered improperly stored vaccines doses; This spontaneous report was received from a registered nurse, concerning a patient of unspecified age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions, allergies and concomitant medications were not reported.   On 11-APR-2019, the patient was vaccinated with improperly storage doses of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) for prophylaxis, lot #R034700 and expiration date 16-JUN-2020 (strength, dose, frequency and route of administration were not reported); with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) for prophylaxis, lot #R033080 and expiration date 06-JUN-2020 (strength, dose, frequency and route of administration were not reported); and with hepatitis a vaccine, inactivated (VAQTA) for prophylaxis lot #S001485, expiration date 12-MAY-2020 and lot #R012988 and expiration date 30-MAY-2019. No adverse effects were reported.   The temperature excursion was reported as below 36°F (35.4°F) during a time frame of 27 minutes. Previous temperature excursion was reported as below 36°F (35.4°F) during a time frame of 15 minutes.   A digital data logger was involved.   This is one of several reports received from the same  reporter.; Sender's Comments:  US-009507513-1904USA012221 : US-009507513-1905USA002744: US-009507513-1905USA002745: US-009507513-1905USA002746: US-009507513-1905USA002748: US-009507513-1905USA002749: US-009507513-1905USA002750: US-009507513-1905USA002751: US-009507513-1905USA002752: US-009507513-1905USA002753: US-009507513-1905USA002754: US-009507513-1905USA002755: US-009507513-1905USA002756: US-009507513-1905USA002757: US-009507513-1905USA002758: US-009507513-1905USA002759: US-009507513-1905USA002760: US-009507513-1905USA002761: US-009507513-1905USA002762: US-009507513-1905USA002763: US-009507513-1905USA002764: US-009507513-1905USA002765: US-009507513-1905USA002766: US-009507513-1905USA002767: US-009507513-1905USA002768: US-009507513-1905USA002769: US-009507513-1905USA002770:
Chills, slight headache, fatigue. Then fever 101 degrees. Subsided after taking Advil and sweating. Fever broke. 20 hours total reaction after second shot.
Information has been received from a 45 year old female consumer with "multiple chemical sensitivity", secondary adrenal insufficiency, hypoglycaemia, asthma, reactive airways disease. The patient can't take NSIADs and was allergic to Tetanus toxoid which caused muscle spasms and local anesthetics caused her throat to swell. On 01-SEP-2009 the patient was vaccinated with a 0.5 mL dose of PNEUMOVAX 23. Concomitant therapy included hydrocortisone, FLOVENT, SINGULAIR, ZYRTEC, ASTELIN, PROTONIX, MAXAIR and josamycin propionate. It was reported that about 4 hours after getting the injection, the patient developed a wheal at the injection site. The next day, it "grew to 7X 3.5". It was painful and the patient couldn't sleep on it for the four days. It was also reported that the patient in 2001 had gotten a dose of "pneumonia shot" (name and manufacturer of the vaccine unknown). There was no AE to the "pneumonia shot". The patient also stated that she didn't know if the AE she called to report from the first "pneumonia shot" or not. The patient sought unspecified medical attention. Within 2 weeks or getting the pneumococcal vaccine, the patient had recovered. No further information is available.
I felt a little funny about an hour after the  vaccine and then that seem to pass, I went to bed and  was awoken by an erratic heart beat
is experiencing significant pain limiting arm movement and redness at the site of injection; is experiencing significant pain limiting arm movement and redness at the site of injection; is experiencing significant pain limiting arm movement and redness at the site of injection; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  An 18-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Sep2022 as dose 4 (booster), single (Batch/Lot number: unknown), in arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for COVID-19 Immunization; Bnt162b2 (DOSE 2, SINGLE), for COVID-19 Immunization; Bnt162b2 (DOSE 3, (BOOSTER) SINGLE), for COVID-19 Immunization.  The following information was reported: VACCINATION SITE PAIN (non-serious), INJECTED LIMB MOBILITY DECREASED (non-serious), VACCINATION SITE ERYTHEMA (non-serious) all with onset Sep2022, outcome "unknown" and all described as "is experiencing significant pain limiting arm movement and redness at the site of injection". Therapeutic measures were taken as a result of vaccination site pain, injected limb mobility decreased, vaccination site erythema.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
This case was reported by a healthcare professional (wife of the subject) and described the occurrence of injection site reaction in a 76-year-old male subject who was vaccinated with FLULAVAL (GlaxoSmithKline). On 22 September 2010 the subject received a dose of FLULAVAL in the left arm. At an unspecified time after vaccination with FLULAVAL, the subject experienced an injection site reaction described as pseudogout causing his hand to be almost paralyzed. It was reported that the subject had experienced a similar reaction to Merck's flu vaccine previously (year not specified). It was noted that the subject may have possibly forgotten about his history and the new doctor's office did not have the documentation. These events required the subject to receive prednisone, which was reported to be affecting his blood sugars. The doctor that the subject visited to received treatment for the reaction thought that this condition may have possibly been Guillain Barre, but then determined that not to be the case. According to the reporting nurse (wife of the subject), the subject should have been admitted to the hospital, but was not as of yet. It was noted to be a possibility given the subject's condition. In the reporter's opinion, the subject should receive intravenous antibiotics in the hospital. The healthcare professional considered the event was disabling, life threatening and clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified.
Broke out in hives 24 hr after vaccine - all over body - responded to BENADRYL.
Loss of circulation, cold, numbness and pain to 1st finger right hand within 2 hours of injection. Since then severe pain and loss of circulation and numbness to both hands and toes.
Had heart attack. Learned he also has a bulge in his Aorta .Then we learned his cancer returned after being cured 10 years ago of it. He had been placed in a study group of Men with this type of cancer the first time he got it. The study found that once cured, the cancer does not return.
Approx 12 hrs after Tdap administered pt developed numbness at site, 36 hrs later noted to have erythema, swelling and heat at site. Apprx 6x7 cm, painful
Nickel size purple indentation (L) deltoid associated at times with pain (L) deltoid. T-97.5.
Initial report received from a healthcare professional, who was also the patient, via Merck, on 31 October 2014. A 27-year-old male patient received a smallpox vaccine (manufacturer, lot number, and date of administration not reported) "many years ago" and subsequently experienced an unspecified adverse event. No information was reported regarding onset date, type of reaction, treatment, or outcome, and the patient (a physician) did not wish to be contacted for any additional information. The patient outcome is unknown. Documents held by sender: none.
This spontaneous report as received from a consumer refers to a her son of unknown age. The patient was vaccinated with 2 doses of GARDASIL (lot number, route, site not reported) on schedule approximately in 2012. The patient was supposed to receive the last dose in December 2012 and had not received the dose at reporting time due to office scheduling delays. The outcome of the event was unknown. It was unspecified if the patient had sought medical attention. Additional information is not expected.
I first became light headed and had a headache about 28 hrs after my second vaccination.  About 12 hours after that I woke up with full on vertigo symptoms.  The room as literally spinning and I could not walk because of it.  I am now 6 days in to this and I have serious dizziness and have not been able to drive a car since the day after the shot.  I have had problems with vomiting and am only comfortable while sitting down and not moving around much.  This doesnt feel right to me and seems like the side effects should have worn off by now.
Eight days after first vaccine, I was awakened early in the morning by loud, high-pitched  ringing in both ears.  I'd had slight tinnitus for about 3 years, but this was many times greater.  I had not heard about this as a possible side effect from the vaccine, so it was not an imagined side effect.  I became very afraid, but could not get an appointee with an ENT doctor for over 2.5 months.  It is tomorrow.  Because of fear, I have  not had my second vaccine.
headaches; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headaches) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (headaches). At the time of the report, HEADACHE (headaches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication provided. No treatment medication provided.
CMA (Certified Medical Assistant) administered 0.25mL instead of 0.5mL.
Pt received Pneumococcal vaccine on 12/05/2003.  Pt states she had a local reaction (size of tomato). She has "flu" like symptoms with fever for 3 days.  Pt used cold/warm compresses and Tylenol.
I received my first dose of COVID-19 (Pfizer) vaccine on 3/25/21, second dose was received on 4/15/21. My menstrual cycle was supposed to start on 04/10/21, as of 4/25/21 I am 15 days late. My menstrual cycles are normal and predictable, with cycles lasting 25-26 days, and pre-menstrual symptoms starting about 5 days prior to initial bleed. I have never had a missed or have had a late menstrual cycle with the exception of pregnancy. All pregnancy tests have come back negative. Since receiving the COVID-19 vaccine, there have been no changes in my lifestyle, diet, or mental health which would lead me to believe caused this late/missed menstrual cycle. As of 4/25/21 still no sign of my menstrual cycle or pre-menstrual symptoms.
Severe rashes covering my entire body after 6 days of the second COVID-19 vaccine. The rashes are getting worse daily and very itchy and swollen.
Low balance. My mom fell at night, she is experiencing loss of balance after the booster shot.
1. Tinnitus, increase in intensity, rest, no change in intensity, no resolution/permanent.  2. Heart Palpitations, increased form occasional to ~100 episodes per day. Rest and oral fluids. Sx continued for ~4 weeks and have slowly decreased to ~10 episodes per day.
Patient received a Pfizer covid vaccine on 9/12/2022 which had expired on 8/31/22. Vaccines removed from refrigerator and discarded. State notified. Patient notified and made aware that would need dose repeated. Vares form completed and faxed.
This is a spontaneous report received from a contactable consumer from medical information team. A male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection), administration date 22Jan2021 (Batch/Lot number: unknown) as dose 1, single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 2021, outcome "unknown", described as "sore arm". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected. Sender's Comments: Linked Report(s) : US-PFIZER INC-2021391253 same reporter, same suspect drug, similar events, different patients.
1st vax on 9/25/98, 2nd vax on 10/17/98, 3rd vax on 11/4/98, 4th vax on 4/30/99. Began symptoms end of Feb/1999, insomia, migraine h/a, muscle pain in legs while lying down, joint pain in legs, hair loss (patch in back of head), equilibrium
pt recv vax 26JUN98 & same day exp fainting w/in 5min of vax;27JUL98 pt exp dizziness;the reporting MD noted that the pt did recover;
Headache; This is a spontaneous report from a contactable consumer or other non hcp. A 36-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection), dose 2 via an unspecified route of administration, administered in Arm Left on 16Jun2021 (at the age of 36 years old) (Batch/Lot Number: EW0217) as single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. Previously the patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 26May2021 (at the age of 36 years old) (Batch/Lot Number: EW0168, Expiry date: 31Aug2021) as single dose for COVID-19 immunisation and experienced no reactions. The patient stated that she got vaccine like yesterday and now on 17Jun2021 experienced headache. She enquired if this is safe to eat the medicine for the headache. No treatment was received in response to adverse event. The outcome of the event was not recovered.  Information on Lot/Batch number was available. Additional information has been requested.
Initial unsolicited report received from a non-healthcare professional on 20 October 2016. This case involves 38 years old female patient who was vaccinated intramuscularly with a dose of FLUZONE QIV (batch number: UT5673KA, expiry date: 30 June 2017, dose in series was not reported) in an unknown site on 06 October 2016. The patient had not reported any medical history. Patient illness at time of vaccination were reports as none, pre-existing physician diagnosed allergies, and birth defects included NKDA (no known drug allergies) and medical conditions not reported. Allergies was reported as none. The patient had not reported any concomitant medications. On 06 October 2016, same day following the vaccination, the patient developed vaccination site rash. The patient had not reported any lab data and the patient had not received any corrective treatment. On 11 Oct 2016, patient recovered from the event. List of documents held by sender: none.
pt recvd vax;to ofc for leg pain;10oct94 devel redness, swelling & huge water like blister at inject site on lt arm;tx oruvail;md felt sxs related to vax;f/u indicated that md has no knowledge about the vax;
Woke up to a severe migraine, felt like vomiting but couldn?t (dry heaves), chills...no fever although felt hot/cold, upset stomach (diarrhea), and tingly face
14 year old Vaccinated with Moderna COVID-19 Vaccine; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (14 year old Vaccinated with Moderna COVID-19 Vaccine) in a 14-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jul-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (14 year old Vaccinated with Moderna COVID-19 Vaccine). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (14 year old Vaccinated with Moderna COVID-19 Vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication details was reported. No treatment medication details was reported.   Most recent FOLLOW-UP information incorporated above includes: On 20-Jul-2021: Follow up received contains no new information (NNI)
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided). The patient's healthcare provider, recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 03-OCT-2016, a pharmacist administered the ZOSTAVAX (lot# and route unknown) vaccine to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries. On or about 08-MAY-2017, the patient was treated by a physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
For 2 days after my 2nd shot, I had low fever, chills, headache, aches, tired, and a little nauseated
pt recv vax 6NOV98 & 7 days later child devel an inj site rxn characterized by redness & warmth;
Patient received first dose of pfizer vaccine to the left deltoid. In observation the patient has a syncopal episode. She was guided to the cot and patient became responsive alert. Paramedics arrived on scene to intervene. No medical intervention was necessary.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: Patient received the vaccine, then used the restroom and came back to wait, 5 minutes post vaccine, he fainted. Regained consciousness when his name was called out, was provided soda and ice pack behind neck. Stated seated, then laid down for a few minutes and then seated upright. EMS was called in to ensure no other injuries.
headache that felt like migraine; high blood pressure; Soreness at the injection site; This spontaneous case was reported by an other (subsequently medically confirmed) and describes the occurrence of INJECTION SITE PAIN (Soreness at the injection site), HEADACHE (headache that felt like migraine) and HYPERTENSION (high blood pressure) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     The patient's past medical history included Vertigo and Stroke.    On 18-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced INJECTION SITE PAIN (Soreness at the injection site). On 24-Jan-2021, the patient experienced HEADACHE (headache that felt like migraine) and HYPERTENSION (high blood pressure). The patient was treated with IBUPROFEN (EXCEDRIN IB) at an unspecified dose and frequency and NAPROXEN (NAPROSYN E) at an unspecified dose and frequency. At the time of the report, INJECTION SITE PAIN (Soreness at the injection site), HEADACHE (headache that felt like migraine) and HYPERTENSION (high blood pressure) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded. Headache and injection site pain are consistent with the product safety profile
Patient is a 31 y.o. female admitted on 5/1/2021     Please refer to the History and Physical report for information on presentation. 31-year-old female with no significant past medical history was admitted to the hospital due to left-sided flank pain radiating to the groin.  CAT scan abdomen pelvis was done which showed 3 mm obstructing ureteric calculi leading to left-sided hydronephrosis.  Additional nonobstructing stones of both kidneys were also noted.  Patient was started on Flomax for pain management.  UA was also grossly positive, patient was started on ceftriaxone.  Urology was consulted, recommended stent placement if patient unable to pass stone.  However patient was able to pass stone within 24 hours.  Patient will be discharged home on Ceftin to complete 7 days course.  Blood sugars were also noted to be elevated during her hospital course.  A1c not back at the time of discharge.  Patient was instructed to follow-up with her PCP, for results of A1c, and up titration of medication.  Patient will be discharged on 500 mg Metformin.  Patient understands the plan
This spontaneous report as received from a pharmacy technician refers to a patient of unknown age and gender. On an unknown dates, the patient was vaccinated with a series of an unspecified HPV vaccine (manufacturer unknown) (lot #, expiration date were not reported). On an unknown dates since completion of the first series, the patient received 2 doses of GARDASIL 9 (lot #, expiration date were not reported). No adverse effects were reported. Additional information has been requested.
SARS COV2 POSITIVE ON 7/20; EXPIRED 8/29/2021
the evening following vax pt lt upper arm became painful & markedly swollen;seen as emergency 24DEC96;DPH given;complaint lasted 4-5 days & caused loss of work;
Vaccine error administered by other provider discovered upon chart review. A five year old patient received the Pfizer 5 - 11 year monovalent covid vaccine instead of the recommended Pfizer 6 month - 4 year monovalent covid vaccine for their second dose. The patient was 4 years at the time of their first covid vaccination so current CDC guidance for persons who turn from 4 to 5 years during the series and began their covid vaccine series with the Pfizer 6 month - 4 year vaccine is for the person to complete two doses of the Pfizer 6 month - 4 year monovalent vaccine and then a third dose of the Pfizer 6 month - 4 year bivalent vaccine at least 8 weeks after the second dose. The patient has experience no adverse effects. The error was reported to and reviewed with the mother of the patient today.
Information has been received from a registered nurse concerning a 9 month old female who on 16-SEP-2009 was vaccinated with a dose of PNEUMOVAX 23 vaccine instead of a flu shot due to human error. No adverse effects noted. The patient sought unspecified medical attention. Additional information has been requested.
Received my 2 doses of Moderna vaccines, had my routine mammogram in July 4 months later- abnormal finding in right breast
Diagnosed with COVID arm. Unable to move arm or complete daily tasks.  Excruciating pain for 7 days now